Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15387431 | 1.00 | LTA4H (0.60) | LTA4HALDH1A1MAPK1L3MBTL1SLC15A1 | |
| Hydrochloric Acid SCHEMBL25286512 | 1.00 | LTA4H (0.60) | LTA4HALDH1A1MAPK1L3MBTL1SLC15A1 | |
| SCHEMBL12155266 | 0.99 | LTA4H (0.61) | LTA4HALDH1A1MAPK1L3MBTL1SLC15A1 | |
| SCHEMBL7740145 | 0.99 | LTA4H (0.61) | LTA4HALDH1A1MAPK1L3MBTL1SLC15A1 | |
| SCHEMBL7740147 | 0.99 | LTA4H (0.61) | LTA4HALDH1A1MAPK1L3MBTL1SLC15A1 | |
| SCHEMBL8698981 | 0.91 | LTA4H (0.56) | LTA4HALDH1A1MAPK1L3MBTL1SLC15A1 | |
| Hydrochloric Acid SCHEMBL29400992 | 0.90 | LTA4H (0.55) | LTA4HALDH1A1MAPK1L3MBTL1SLC15A1 | |
| SCHEMBL28119343 | 0.89 | LTA4H (0.52) | LTA4HALDH1A1MAPK1L3MBTL1SLC15A1 | |
| SCHEMBL28119342 | 0.89 | LTA4H (0.52) | LTA4HALDH1A1MAPK1L3MBTL1SLC15A1 | |
| SCHEMBL9716820 | 0.88 | LTA4H (0.56) | LTA4HALDH1A1MAPK1L3MBTL1SLC15A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | Technische Universität München (DE) | 2026-03-17 | — | — | US | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250295819-A1 | PSMA binding dual mode radiotracer and therapeutics | UNIV MUENCHEN TECH (DE) | 2025-09-25 | — | — | US | disclosed |
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| US-12377176-B2 | Cancer diagnostic imaging agents | Technische Universität München (DE) | 2025-08-05 | — | — | US | disclosed |
| US-12357711-B2 | PSMA binding dual mode radiotracer and therapeutic | Technische Universität München (DE) | 2025-07-15 | — | — | US | disclosed |
| US-12268759-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4520745-A2 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | Cornell University (US) | 2025-03-12 | — | — | EP | disclosed |
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| EP-3474903-B1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | UNIV CORNELL (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20170057912-A1 | PROCESS FOR MAKING LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-03-02 | — | — | US | disclosed |
| EP-3127604-A1 | LYSIN-GLUTAMIC ACID DIPEPTIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-02-08 | — | — | EP | disclosed |
| US-9522874-B2 | Lysine-glutamic acid dipeptide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-2849882-A1 | LYSIN-GLUTAMIC ACID DIPEPTIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-03-25 | — | — | EP | disclosed |
| US-20150073173-A1 | LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-03-12 | — | — | US | disclosed |
| CN-104271227-A | Lysin-glutamic acid dipeptide derivatives | HOFFMANN LA ROCHE | 2015-01-07 | — | — | CN | disclosed |
| WO-2013171135-A1 | LYSIN-GLUTAMIC ACID DIPEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| EP-2664374-A1 | Lysin-glutamic acid dipeptide derivatives | F. Hoffmann-La Roche AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377176-B2 | Cancer diagnostic imaging agents | FOLH1, FOLR1, KLK3 | LTA4H 4594/4885ALDH1A1 1382/4885MAPK1 3975/4885 |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | LTA4H 1788/4885ALDH1A1 3047/4885MAPK1 1691/4885 |
| US-12357711-B2 | PSMA binding dual mode radiotracer and therapeutic | PSMA2, FOLH1, PSMA1 | LTA4H 4230/4885ALDH1A1 2013/4885MAPK1 3294/4885 |
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | LTA4H 3191/4885ALDH1A1 1271/4885MAPK1 4664/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | LTA4H 2762/4885ALDH1A1 3743/4885MAPK1 2202/4885 |
| US-20250295819-A1 | PSMA binding dual mode radiotracer and therapeutics | FOLH1, PSMA2, PSMA1 | LTA4H 4176/4885ALDH1A1 2008/4885MAPK1 3257/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | LTA4H 3810/4885ALDH1A1 3909/4885MAPK1 470/4885 |
| US-12268759-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | LTA4H 3191/4885ALDH1A1 1271/4885MAPK1 4664/4885 |
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | KLK3, FOLH1, SLC7A1 | LTA4H 3407/4885ALDH1A1 2396/4885MAPK1 1950/4885 |
| US-20170057912-A1 | PROCESS FOR MAKING LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES | GLUL, ASNS, QPCT | LTA4H 475/4885ALDH1A1 2242/4885MAPK1 1610/4885 |
| US-20150073173-A1 | LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES | GLUL, ASNS, QPCT | LTA4H 431/4885ALDH1A1 2435/4885MAPK1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.